Prospective randomized phase IV open label comparative study of dalteparin vs unfractionated heparin in high risk patients of non-ST elevation acute coronary syndromes intended for early invasive strategy.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary) ; Heparin
Indications Acute coronary syndromes; Embolism and thrombosis
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

14 Oct 2011 Actual initiation date (Jun 2007) added as reported by ClinicalTrials.gov.
10 Mar 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
10 Mar 2009 Actual patient number (175) added as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight